Personalized Medicine: New Perspectives – New Ethics?

• Editorial: Defining a new bioethic. Nature Genet.28, 297–298 (2001).
   PubMed Web of Science ®Google Scholar
• Chadwick R , BergK: Solidarity and equity: new ethical frameworks for genetic databases.Nature Rev. Genet.2, 318–321 (2001).
   PubMed Web of Science ®Google Scholar
• Boshier A , ShakirSAW, TelferP, BehrE, PakrashiT, CammAJ: The negative effect of red tape on research.Pharmacoepidemiol. Drug Safe.14, 373–376 (2005).
   PubMed Web of Science ®Google Scholar
• Dumville JC , WatsonJ, RaynorP, Torgerson DJ: Research governance: a barrier to ethical research? QJM97(3), 113–114 (2004).
   PubMed Web of Science ®Google Scholar
• Lunshof JE : Desperate times call for desperate measures.Nature Rev. Genet.7, 162 (2006).
   Web of Science ®Google Scholar
• Glasziou P , ChalmersI: Ethics review roulette: what can we learn?BMJ328, 121–122 (2004).
   PubMed Web of Science ®Google Scholar
• Wald DS : Bureaucracy of ethics applications.BMJ329, 282–284 (2004).
   PubMed Web of Science ®Google Scholar
• Ruaño G : Quo vadis personalized medicine?Personalized Med.1(1), 1–7 (2004).
   PubMedGoogle Scholar
• Lunshof JE : Personalized medicine: how much can we afford? A bioethics perspective.Personalized Med.2(1), 43–47 (2005).
   PubMedGoogle Scholar
• De J ong FA, de Jonge MJ, Verweij J, Mathijssen RH: Role of pharmacogenetics in irinotecan therapy. Cancer Lett.234(1), 90–106 (2005).
   PubMed Web of Science ®Google Scholar
• Cheok MH , LugthartS, EvansWE: Pharmacogenomics of acute leukemia.Annu. Rev. Pharmacol. Toxicol.46, 317–353 (2006).
   PubMed Web of Science ®Google Scholar
• Lee W , LockhartAC, KimRB, RothenbergML: Cancer pharmacogenomics: powerful tools in cancer chemotherapy ad drug development.The Oncologist10, 104–111 (2005).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , FuhrU, BrockmöllerJ: Pharmacogenetics-based therapeutic recommendations – ready for clinical practice?Nature Rev. Drug Discov.4, 639–647 (2005).
   PubMed Web of Science ®Google Scholar
• Dorado P , CáceresMC, Pozo-GuisadoE, WongML, LicinioJ, LlerenaA: Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.Bio Techniques39, 571–574 (2005).
   PubMed Web of Science ®Google Scholar
• Sconce EA , KhanTI, WynneHA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.Blood106, 2329–2333 (2005).
   PubMed Web of Science ®Google Scholar
• Royal Society working group on pharmacogenetics. Personalised medicines: hopes and realities.The Royal Society (2005).
   Google Scholar
• Pirmohamed M , JamesS, MeakinS et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients.BMJ329, 15–19 (2004).
   PubMed Web of Science ®Google Scholar
• Hedgecoe A : The Politics of Personalized Medicine. Pharmacogenetics in the clinic.Cambridge University Press, Cambridge, UK (2004).
   Google Scholar
• Woelderink A , IbarretaD, HopkinsMM, Rodriguez-CerezoE: The current clinical practice of pharmacogenetic testing in Europe: TPMTand HER2 as case studies.Pharmacogenomics J.6, 3–7 (2006)
   PubMed Web of Science ®Google Scholar
• Bartlett JM : Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy.Am. J. Pharmacogenomics5(5), 303–315 (2005).
   PubMedGoogle Scholar
• Church GM : The personal genome project. Editorial.Mol. Syst. Biol. Epub December 13, 2005. DOI:10.1038/msb4100040.
   Google Scholar
• Shendure J , MitraRD, VarmaC, Church GM: Advanced sequencing technologies: methods and goals. Nature Rev. Genet5, 335–344 (2004).
   PubMed Web of Science ®Google Scholar
• Kahn J : Misreading race and genomics after BiDil.Nature Genet.37(7), 655–656 (2005).
   PubMed Web of Science ®Google Scholar
• Holden C : Race and medicine.Science302, 594–596 (2003)
   PubMed Web of Science ®Google Scholar
• Bamshad MJ , WoodingS, WatkinsWS, OstlerCT, BatzerMA, JordeLB: Human population genetic structure and inference of group membership.Am. J. Hum. Genet.72, 578–589 (2003).
   PubMed Web of Science ®Google Scholar
• Klein TE , ChangJT, ChoMK et al.: Integrating genotype and phenotype information: an overview of the PharmGKB project.Pharmacogenomics J.1, 167–170 (2001).
   PubMedGoogle Scholar
• McCarthy CA , WilkeRA, GiampietroGF, WesbrookSD, CaldwellMD: Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank.Personalized Med.2(1), 49–79 (2005).
   PubMedGoogle Scholar
• Cambon-Thomsen A : The social and ethical issues of postgenomic human biobanks.Nature Rev. Genet5, 866–873 (2004).
   PubMed Web of Science ®Google Scholar
• Gurwitz D , LunshofJE, AltmanRB: A call for the creation of personalized medicine databases.Nature Rev. Drug Discov.5, 23–26 (2006).
   PubMed Web of Science ®Google Scholar
• Kohane IS , AltmanRB: Health-information altruists – a potentially critical resource.N. Engl. J. Med.353(19), 2074–2077 (2005).
   PubMed Web of Science ®Google Scholar
• Gottesman II , ToddDG: The endophenotype concept in psychiatry: etymology and strategic intentions.Am. J. Psychiatry160, 636–645 (2003).
   PubMed Web of Science ®Google Scholar
• Nuremberg Code. Trials of war criminals before the Nuremberg Military Tribunals under Control Council Law. US Government Printing Office, Washinton DC, USA, 181–182 (1949).
   Google Scholar
• The Belmont Report. National Commission for the Protection of Human Subjects in Biomedical and Behavioral Research. DHEW Publications, Washington DC, USA (1979).
   Google Scholar
• The Declaration of Helsinki. World Medical Association (1964). Edinburgh, Scotland (2000).
   Google Scholar
• Universal Declaration on Bioethics and Human Rights. UNESCO (2005).
   Google Scholar
• Häyry M , TakalaT: Human dignity, bioethics and human rights.Developing World Bioeth.5 (3) 225–233 (2005)
   PubMedGoogle Scholar
• Beauchamp TL , ChildressJF: Principles of biomedical ethics. Fifth edition. Oxford University Press, Oxford, UK (2001).
   Google Scholar
• Knoppers BM , ChadwickR: Human genetic research: emerging trends in ethics.Nature Rev. Genet.6, 75–79 (2005).
   PubMed Web of Science ®Google Scholar
• Beauchamp TL : Philosophical Ethics. An Introduction to Moral Philosophy. Second Edition.McGraw-Hill, New York, USA (1991).
   Google Scholar
• Williams JR : UNESCO‘s proposed Declaration on Bioethics ad Human Rights – a bland compromise.Developing World Bioeth.5(3), 210–215 (2005).
   PubMedGoogle Scholar
• Kopelman LM : The incompatibility of the United Nation‘s goals and conventional ethical relativism.Developing World Bioeth.5(3), 234–243 (2005).
   PubMedGoogle Scholar
• Selgelid MJ : Universal norms and conflicting values.Developing World Bioeth.5(3), 267–273 (2005).
   PubMedGoogle Scholar
• Knoppers BM , ChadwickR: The Human Genome Project: under an international ethical microscope.Science265, 2035–2036 (1994).
   PubMed Web of Science ®Google Scholar
• Lee SSJ : Personalized medicine and pharmacogenomics: ethical and social challenges.Personalized Med.2(1), 29–35 (2005).
   PubMedGoogle Scholar
• Harris J , SulstonJ: Genetic equity.Nature Rev. Genet.5, 796–800 (2004).
   PubMed Web of Science ®Google Scholar
• Caulfield T , BrownswordR: Human dignity: a guide to policy making in the biotechnology era?Nature Rev. Genet.7, 72–76 (2006).
   PubMed Web of Science ®Google Scholar
• Renegar G , WebsterCJ, StuerzebecherS et al.: Returning genetic research results to individuals: points to consider. Bioethics20(1), 24–36 (2006).
   PubMed Web of Science ®Google Scholar

Websites

• The Royal Society. www.royalsoc.ac.uk/displaypagedoc.asp?id=15874
   Google Scholar
• The Personal Genome Project (PGP). http://arep.med.harvard.edu/PGP/
   Google Scholar
• The Phamacogenomics and Pharmacogenetics Knowledge Base (PharmGKB). www.pharmgkb.org
   Google Scholar
• The World Medical Association. www.wma.net
   Google Scholar
• UNESCO. http://portal.unesco.org/
   Google Scholar